Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 12, 2026 · Material agreement · Investor press release · Financial statements
Enliven Therapeutics, Inc.
14
Material agreement
Jun 12, 2026
| ItemItem | Disclosure |
|---|---|
| Item 1.01 | Entered a material definitive agreement |
| Item 7.01 | Regulation FD disclosure (investor press release or presentation) |
| Item 9.01 | Financial statements and exhibits |
Enliven Therapeutics, Inc. filed this to report entering into or terminating a material contract that could affect operations, partnerships, or future hiring.
1 Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants BURLINGAME, CA, June 11, 2026 /PRNewswire/ — Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has priced its previously announced upsized underwritten public offering of 8,933,334 shares of its common stock at a price to the public of $37.
This filing reports Item 1.01 (entered a material definitive agreement). These item codes often precede or accompany restructuring, leadership changes, or deals that can shift headcount.
Enliven Therapeutics, Inc. reported material events that can affect workforce planning. cutoffs surfaces the filing alongside WARN layoffs, H-1B activity, and company signals.
